Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 181Colorectal Neoplasms 144Stomach Neoplasms 90Rectal Neoplasms 90Pancreatic Neoplasms 74Neoplasm Metastasis 60Neoplasms 48Colonic Neoplasms 40Esophageal Neoplasms 31Gallbladder Neoplasms 18Biliary Tract Neoplasms 17Bile Duct Neoplasms 17Carcinoma, Hepatocellular 15Triple Negative Breast Neoplasms 13Cholangiocarcinoma 12Adenocarcinoma 12Unspecified Adult Solid Tumor, Protocol Specific 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Liver Neoplasms 10Breast Neoplasms, Male 10Adenocarcinoma Of Esophagus 10Squamous Cell Carcinoma of Head and Neck 9Head and Neck Neoplasms 9Gastrointestinal Neoplasms 9Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Uterine Cervical Neoplasms 5

Interventions

ganitumab 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2dalotuzumab 1conatumumab 1cixutumumab 1Sorafenib 1Receptor Protein-Tyrosine Kinases 1Paclitaxel 1Lapatinib 1Istiratumab 1Cisplatin 1Capecitabine 1BIIB022 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Insulin-Like Growth Factor I, Resistance To × Capecitabine × Clear all
NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
64 enrolled 13 charts
Breast

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡